# Stem cells weekly update - public article updated Date: 2026-09-14 Site: Managing Expectations / Health Primary article: `/blog/articles/stem-cells-evidence-costs-risks-global-guide.html` Previous weekly note: `/research/health/stem-cells-weekly-update-2026-09-07.md` ## Bottom line A small public article update is warranted. No broad stem-cell cure claim, orthopedic proof upgrade, clinic endorsement, anti-aging evidence shift, or medical-tourism recommendation was found. The meaningful update is evidence-quality and safety framing from newly indexed peer-reviewed items: - A New England Journal of Medicine phase 3 pediatric report on exagamglogene autotemcel (exa-cel/CASGEVY-related autologous CRISPR-edited hematopoietic stem-cell therapy) in children ages 5-11 with transfusion-dependent beta-thalassemia or sickle cell disease reported strong early outcomes among evaluable children, but every treated child had at least one grade 3 or 4 adverse event and one child died from severe veno-occlusive liver disease assessed as related to busulfan conditioning. Evidence label: regulated, disease-specific, high-intensity transplant/gene-editing medicine; not a general commercial stem-cell-clinic signal. - A first-in-human Cell paper on glycocalyx-edited autologous MSCs for advanced osteoporosis in 10 women reported no serious adverse events and fracture/BMD signals over long follow-up. Evidence label: early, small, specialist trial; promising/under study only. - New orthopedic and graft-versus-host-disease publications reinforced the same split: some carefully manufactured cellular therapies may generate useful signals in defined settings, while broad cash-pay claims remain unsupported without product-specific authorization, trial oversight, and long-term follow-up. ## Sources checked this run ### United States - FDA / NIH / NCI / ClinicalTrials.gov - FDA, **Approved Cellular and Gene Therapy Products** URL: https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/approved-cellular-and-gene-therapy-products Retrieval: direct page retrieval succeeded. Finding: FDA page content remains current as of 2026-08-18. The list includes product-specific cellular/gene therapies, including CASGEVY (exa-cel), TREGZI, GENGLYCOS, KRESLADI, OTARMENI and others. This supports the article's existing warning: FDA approvals are narrow and product/indication-specific. - FDA, **Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes** URL: https://www.fda.gov/vaccines-blood-biologics/consumers-biologics/consumer-alert-regenerative-medicine-products-including-stem-cells-and-exosomes Retrieval: web extraction succeeded. Finding: FDA states stem-cell products generally require FDA approval; only blood-forming cord-blood stem-cell products are FDA-approved as stem-cell products in the U.S. for limited blood-production disorders; no exosome products are FDA-approved. FDA continues to warn about orthopedic, neurologic, pulmonary/cardiac, autism, macular degeneration, chronic pain and fatigue claims. - FDA, **Important Patient and Consumer Information About Regenerative Medicine Therapies** URL: https://www.fda.gov/vaccines-blood-biologics/consumers-biologics/important-patient-and-consumer-information-about-regenerative-medicine-therapies Retrieval: web extraction succeeded. Finding: FDA continues to warn that unapproved regenerative products include stem cells, stromal vascular fraction, umbilical cord blood/cord cells, amniotic fluid, Wharton's jelly, ortho-biologics and exosomes, and reports serious harms including blindness, tumor formation, infections and neurologic events. - FDA warning-letter search scan Query: `site:fda.gov stem cell exosome warning letter September 2026 regenerative medicine FDA` and related warning-letter searches. Finding: No newer FDA regenerative/stem-cell warning letter after the August 2026 R3 item already added on September 7 was verified in this run. - ClinicalTrials.gov scan Finding: Current Parkinson's disease iPSC/dopaminergic progenitor listings remain trial/registry signals only. They do not change the article's evidence labels or justify clinic claims. ### Canada - Health Canada - Health Canada, **Unauthorized cell therapy warning** URL: https://recalls-rappels.canada.ca/en/alert-recall/health-canada-advising-canadians-about-potential-health-risks-associated-unauthorized Retrieval: web extraction succeeded. Finding: Health Canada continues to state that all cell therapies are considered drugs under the Food and Drugs Act and must be authorized before being offered to Canadians. Unauthorized treatments may be unproven and carry serious, life-altering or life-threatening risks. - Health Canada, **Policy Position Paper - Autologous Cell Therapy Products** URL: https://www.canada.ca/en/health-canada/services/drugs-health-products/biologics-radiopharmaceuticals-genetic-therapies/applications-submissions/guidance-documents/cell-therapy-policy.html Retrieval: web extraction succeeded. Finding: Health Canada continues to state that autologous cell therapy products, except narrow minimally manipulated/homologous lymphohematopoietic uses in transplantation, are regulated as drugs/new drugs and require Health Canada authorization or clinical-trial authorization. ### Guidelines / professional societies - ISSCR, **Guidelines for Stem Cell Research and Clinical Translation** URL: https://isscr.org/guidelines Retrieval: web extraction succeeded. Finding: Current visible page is version 1.2 / August 2025 update. ISSCR continues to emphasize rigor, oversight, transparency and evidence-based clinical translation. No new guideline change requiring a public evidence-label shift. - ISSCR, **Policy** URL: https://www.isscr.org/policy Retrieval: web extraction succeeded. Finding: ISSCR continues to oppose premature marketing of unproven stem-cell treatments and supports rigorous transparent oversight. - AAOS OrthoInfo, **Use of Stem Cells in Orthopaedics** URL: https://orthoinfo.aaos.org/en/treatment/use-of-stem-cells-in-orthopaedics/ Retrieval: web extraction succeeded. Finding: AAOS continues to frame orthopedic stem-cell use as an area with confusion, evolving mechanisms, and ongoing evidence limits. No orthopedic-efficacy upgrade was found. ### Global regulatory scan - EMA, **Advanced therapy medicinal products: Overview** URL: https://www.ema.europa.eu/en/human-regulatory-overview/advanced-therapy-medicinal-products-overview Retrieval: web extraction succeeded. Finding: EMA continues to classify gene therapy medicines, somatic-cell therapy medicines and tissue-engineered medicines as ATMPs, and warns that unregulated advanced therapies may put patients at risk without proven benefit. - Japan PMDA regenerative medical products review reports URL: https://www.pmda.go.jp/english/review-services/reviews/approved-information/0004.html Retrieval: web extraction was rate-limited during this run; search-result text was treated as a lead only. Finding: No new PMDA-specific public claim was added. ### Peer-reviewed / PubMed / PMC scan - PubMed ESearch date-window scan, 2026-09-07 to 2026-09-14 Retrieval: NCBI ESearch/ESummary succeeded. Query groups included stem-cell therapy clinical trials, MSC therapy, iPSC therapy, exosome/adverse-event terms, HSCT, Parkinson's, diabetes, spinal cord, arthritis, autoimmune disease, cancer and safety. Finding: No single paper changed the broad guidance. Several source-worthy items were identified for a narrow weekly update. - NEJM / PubMed, **Exa-cel in Children with Transfusion-Dependent beta-Thalassemia or Sickle Cell Disease** URL: https://pubmed.ncbi.nlm.nih.gov/42274009/ DOI: 10.1056/NEJMoa2603387 Retrieval: web extraction succeeded. Finding: Ongoing phase 3, open-label, single-group pediatric studies in children ages 5-11. Among evaluable children followed at least 16 months, 8/8 with transfusion-dependent beta-thalassemia were transfusion independent and 8/8 with sickle cell disease were free of severe vaso-occlusive crises. All children had grade 3 or 4 adverse events; two had severe veno-occlusive liver disease related to busulfan conditioning and one died. Evidence label: strong disease-specific specialist evidence with major conditioning risks; not a general stem-cell-clinic endorsement. - Cell / PubMed, **Glycocalyx-edited mesenchymal stem/stromal cell therapy in advanced osteoporosis** URL: https://pubmed.ncbi.nlm.nih.gov/42727576/ DOI: 10.1016/j.cell.2026.08.017 Retrieval: web extraction succeeded. Finding: First-in-human trial in 10 women with advanced osteoporosis using IV glycocalyx-edited autologous bone marrow-derived MSCs. Abstract reports no serious adverse events, durable fracture reduction signals, increased bone turnover markers, bone tissue area and volumetric BMD. Evidence label: promising/under study; small early trial, not general proof or clinic endorsement. - Stem Cell Reports / PubMed, **Responders vs. non-responders to mesenchymal stromal cells in knee osteoarthritis** URL: https://pubmed.ncbi.nlm.nih.gov/42561945/ DOI: 10.1016/j.stemcr.2026.103024 Retrieval: web extraction succeeded. Finding: Clinical-trial data from NCT02351011 explored donor-batch potency and patient responder features. Abstract reports 42% responders at 24 months and emphasizes heterogeneity. Evidence label: useful mechanism/patient-selection signal; not a broad orthopedic approval or guarantee. - Transplantation and Cellular Therapy / PubMed, **Tomostrocel real-world data in severe refractory acute graft-versus-host disease** URL: https://pubmed.ncbi.nlm.nih.gov/42731730/ DOI: 10.1016/j.jtct.2026.09.021 Retrieval: web extraction succeeded. Finding: Retrospective real-world surveillance data from 317 adults treated outside trials in Europe; day-28 overall response rate 45%, 24-month overall survival probability 28%, favorable safety profile reported; authors state randomized trials are awaited. Evidence label: specialist aGvHD context; observational, not general stem-cell evidence. - Med / PubMed, **Engineered mesenchymal stem cells regulate integrated stress response for fibrosis therapy** URL: https://pubmed.ncbi.nlm.nih.gov/42586072/ DOI: 10.1016/j.medj.2026.101261 Retrieval: web extraction succeeded. Finding: Preclinical engineered-MSC drug-delivery platform in pulmonary/liver fibrosis models. Evidence label: preclinical only. ## What changed - Created this dated source note for audit continuity. - Added a short September 14, 2026 weekly update callout to the article, focused on exa-cel pediatric data and the difference between regulated, disease-specific hematopoietic/gene-edited cell therapy and broad clinic-marketed stem-cell claims. - Added source links for this note, the NEJM/PubMed exa-cel pediatric paper, the Cell/PubMed glycocalyx-edited MSC osteoporosis paper, and the Stem Cell Reports knee-osteoarthritis MSC responder paper. - Updated the article metadata line and sitemap entries for the article and this source note. ## What did not change - No medical advice, dosing, clinic recommendation, or medical-tourism recommendation was added. - No evidence was found that broad cash-pay stem-cell, exosome, anti-aging, orthopedic, neurologic, diabetes, COPD, autism or cancer-cure claims should be upgraded. - Health Canada's core Canadian caution remains unchanged. - ISSCR and AAOS cautionary framing remains unchanged. - ClinicalTrials.gov registry movement remains a monitoring signal, not proof of effectiveness. ## Suggested future monitoring - Track whether exa-cel pediatric data leads to label expansion or formal pediatric regulatory changes; do not treat the trial paper itself as a label change. - Re-check FDA's approved cellular/gene therapy list for new product or indication additions. - Follow iPSC/ESC-derived Parkinson's and diabetes studies, but keep early-phase feasibility distinct from approved care. - Continue scanning FDA warning letters for regenerative, Wharton's jelly, umbilical-cord and exosome enforcement. ## Medical/editorial boundary This note is source tracking only. It is not medical advice, diagnosis, treatment guidance, dosing guidance, trial recruitment advice, clinic endorsement, securities analysis, or encouragement to travel for treatment.